Septerna, Inc Common Stock
Price & Volume
Stats
See moreOpen | $31.37 |
Previous Close | $31.05 |
Day Range | $30.75-$31.41 |
52W Range | $9.11-$32.63 |
Market Cap | $1.3B |
Shares Short | 2M |
Financials
See moreRevenue (12 Mos) | $72.2M |
Revenue Growth (YoY) | 12,011% |
Gross Profit (12 Mos) | $72.2M |
Diluted EPS | -$0.80 |
News
See moreYahoo Finance • 3 months ago
Septerna Reports Positive Phase 1 Data For SEP-631; Plans Phase 2 In CS Urticaria
Yahoo Finance • 3 months ago
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
Yahoo Finance • 5 months ago
Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls
Yahoo Finance • 6 months ago
Septerna to Participate in 8th Annual Evercore Healthcare Conference
About
CEO | Dr. Jeffrey T. Finer M.D., Ph.D. |
Address | 250 East Grand Avenue, South San Francisco, CA, United States, 94080 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 130 |